Copy or Compete? How India’s patent law harms its own drug industry’s ability to innovate
Section 3(d) of India’s patent law may be putting India at a competitive disadvantage. The data presented in this research note shows it is preventing Indian generic pharmaceutical companies from developing new formulations, compositions, and combinations of existing medicines, which they instead undertake and commercialise abroad.